Atrial fibrillation devices market seen reaching $14.77 billion by 2030

The Business Research Company says the atrial fibrillation devices market is set to rise from $8.6 billion in 2025 to $9.61 billion in 2026, with growth driven by aging populations, rising cardiovascular disease and wider use of monitoring and ablation technologies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Atrial fibrillation devices sit at the center of diagnosis and treatment for a heart rhythm disorder tied to stroke risk and broader cardiovascular disease burden. - The market’s projected growth signals rising demand for monitoring, rhythm management and ablation tools as patient counts increase worldwide. - The sector’s expansion matters for hospitals, ambulatory surgical centers, device makers and patients needing earlier detection and treatment.

What happened: - The Business Research Company published a market intelligence report on the atrial fibrillation devices market on July 27, 2026. - The report estimates the market at $8.6 billion in 2025 and $9.61 billion in 2026. - The report projects the market will reach $14.77 billion by 2030. - The report links the near-term growth rate to an 11.7% CAGR from 2025 to 2026. - The report forecasts an 11.3% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Atrial fibrillation devices include implantable cardiac monitors, pacemakers, defibrillators, catheter ablation systems and wearable ECG monitors. - These devices are used to detect, track and treat irregular heart rhythms associated with atrial fibrillation. - Their goals include restoring normal heart rhythm, lowering stroke risk and improving quality of life. - The report says growth has been driven by rising atrial fibrillation cases, an aging population, a larger cardiovascular disease burden, more electrophysiology laboratories and greater use of implantable cardiac devices. - Looking ahead, the report points to technological advances in ablation procedures, wider remote patient monitoring, growing awareness of stroke prevention, growth in ambulatory surgical centers and improvements in mapping and navigation systems. - The report says rising cardiovascular disease worldwide remains a major growth driver. - The report ties that trend to obesity, diabetes, sedentary lifestyles and unhealthy diets. - In June 2024, the American Heart Association said U.S. high blood pressure prevalence is expected to rise from 51.2% to 61.0%. - The American Heart Association also projected U.S. cardiovascular disease cases will rise from 128 million in 2020 to more than 184 million by 2050. - The report says North America benefits from advanced healthcare infrastructure and broad cardiovascular awareness. - The report says Asia-Pacific growth will be supported by higher healthcare investment and a larger elderly population. - The analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, total addressable market analysis, a company scoring matrix, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The company also offered a free sample of the report at Download a free sample. - The full report is available at View the full report.

Between the lines: - The report points to a market shaped by both demographic pressure and clinical technology upgrades. - The combination of rising disease prevalence and broader access to remote monitoring suggests continued demand for devices that support earlier intervention and long-term management. - Regional growth patterns suggest mature markets will remain large, while faster expansion may come from healthcare investment and aging populations in Asia-Pacific.

What's next: - The market is expected to keep expanding through 2030 as ablation, monitoring and navigation technologies advance. - Device makers and healthcare providers will likely focus on stroke prevention, remote care and treatment settings that can handle more patients outside traditional hospitals. - Regional opportunities will differ, with North America remaining a large base and Asia-Pacific carrying the strongest growth outlook.

The bottom line: - Atrial fibrillation devices are moving from a niche heart-rhythm category to a faster-growing global care market, with demand underpinned by aging populations and rising cardiovascular disease.